目的 比較西格列汀與瑞格列奈治療初診2型糖尿?。═2DM）的臨床療效。方法 回顧性分析104例初診T2DM患者的臨床資料，其中54例為西格列汀治療（G組），50例為瑞格列奈治療（R組）。比較兩組治療前后空腹血糖（FPG）、餐后2 h血糖（2 hPG）、糖化血紅蛋白（HbA1c）、總膽固醇（TC）、三酰甘油（TG）、高密度脂蛋白膽固醇（HDL-C）水平及糖化血紅蛋白（HbA1c）達(dá)標(biāo)率、體質(zhì)指數(shù)（BMI）變化量和低血糖發(fā)生率。結(jié)果 兩組治療后的FPG、2hPG、HbA1c水平均明顯低于治療前，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05），但組間差異無(wú)統(tǒng)計(jì)學(xué)意義。兩組治療前后的TG、TC、HDL-C水平均無(wú)明顯變化。兩組HbA1c達(dá)標(biāo)率無(wú)統(tǒng)計(jì)學(xué)意義，G組BMI變化量及低血糖發(fā)生率明顯低于R組，組間差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 西格列汀與瑞格列奈治療初診T2DM患者均能有效降低血糖，對(duì)血脂無(wú)明顯影響，但西格列汀在控制BMI和減少低血糖方面更有優(yōu)勢(shì)。

Objective Tocompare the clinical efficacy of Glipizide and Repaglinide in the treatment of newly diagnosed type 2 diabetes (T2DM). Methods The clinical data of 104 patients with newly diagnosed T2DM were retrospectively analyzed, among them, 54 cases were treated with Glipizide (group G), and 50 cases were treated with Repaglinide (group R). The levels of FPG, 2hPG, HbA1c, TC, TG and HDL-C before and after treatment and HbA1c compliance rates, BMI variation and incidences of hypoglycemia between two groups were compared. Results The levels of FPG, 2hPG and HbA1c after treatment in the two groups were significantly lower than those before treatment (P < 0.05), and there were no significant difference between the groups. There were no significant changes in TG, TC and HDL-C levels before and after treatment in the two groups. There were no significant changes in HbA1c compliance rates between the two groups, and the BMI variation and incidences of hypoglycemia in the group G were significantly lower than those in the group R (P < 0.05). Conclusion BothGlipizide and Repaglinide in the treatment of T2DM can reduce blood glucose effectively, and no significant effect on blood lipids,But Glipizide has more advantages in controlling BMI and reducing hypoglycemia.